Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
E4BP4 CRISPR/Cas9 KO Plasmid (h): sc-401353
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- E4BP4 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the E4BP4 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: E4BP4 Antibody (A-9): sc-74415
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
E4BP4 CRISPR/Cas9 KO Plasmid (h) | sc-401353 | 20 µg | $397.00 |
Overview
NFIL3 encodes the basic leucine zipper transcription factor E4BP4, a context-dependent regulator of gene expression that integrates circadian cues with immune and metabolic programs. E4BP4 influences differentiation and effector function across lymphoid lineages, including regulation of cytokine networks and survival pathways, and contributes to homeostatic control of inflammatory signaling. It also interfaces with transcriptional circuits that shape cellular stress responses and developmental timing, linking rhythmic regulation to broader gene regulatory networks. Dysregulated NFIL3/E4BP4 activity has been associated with immune-mediated pathology, hematologic phenotypes, and altered metabolic and circadian phenotypes in research settings.
E4BP4 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the NFIL3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the NFIL3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the NFIL3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish E4BP4 protein expression.
This CRISPR knockout system enables efficient generation of NFIL3-deficient cell models for investigation of E4BP4 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting NFIL3 exon(s) critical for E4BP4 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple NFIL3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by E4BP4 CRISPR/Cas9 KO Plasmid (h) and E4BP4 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the NFIL3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by E4BP4 HDR Plasmid (h) and E4BP4 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by NFIL3 homology arms to support homology-directed repair at defined NFIL3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.